Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewACET is a potent and selective GluK1 (formerly GluR5) containing kainate receptor antagonist (IC50 = 7 nM) that displays selectivity over GluK2 (formerly GluR6) containing kainate, NMDA, AMPA and group I mGlu receptors. Reversibly blocks induction of NMDA receptor-independent long term potentiation (LTP) in vitro at nanomolar concentrations.
Please refer to IUPHAR Guide to Pharmacology for the most recent naming conventions.
M. Wt | 429.45 |
Formula | C20H19N3O6S |
Storage | Store at RT |
Purity | ≥98% (HPLC) |
CAS Number | 936095-50-0 |
PubChem ID | 16125102 |
InChI Key | LCZDCKMQSBGXAH-AWEZNQCLSA-N |
Smiles | O=C(C(C)=CN1C[C@@H](C(O)=O)N)N(CC2=C(C(O)=O)SC(C3=CC=CC=C3)=C2)C1=O |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solvent | Max Conc. mg/mL | Max Conc. mM | |
---|---|---|---|
Solubility | |||
DMSO | 8.59 | 20 | |
3eq. NaOH | 4.29 | 10 |
The following data is based on the product molecular weight 429.45. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
0.2 mM | 11.64 mL | 58.21 mL | 116.43 mL |
1 mM | 2.33 mL | 11.64 mL | 23.29 mL |
2 mM | 1.16 mL | 5.82 mL | 11.64 mL |
10 mM | 0.23 mL | 1.16 mL | 2.33 mL |
References are publications that support the biological activity of the product.
Dolman et al (2007) Synthesis and pharmacological characterisation of N3-substituted willardiine derivatives: role of the substituent at the 5-position of the uracil ring in the development of highly potent and selective GLUK5 kainate receptor antagonis J.Med.Chem. 50 1558 PMID: 17348638
Dargan et al (2009) ACET is a highly potent and specific kainate receptor antagonist: Characterisation and effects on hippocampal mossy fibre function. Neuropharmacology 56 121 PMID: 18789344
If you know of a relevant reference for ACET, please let us know.
Keywords: ACET, ACET supplier, Potent, antagonists, GluR5-containing, kainate, receptors, Glutamate, Kainate, Receptors, iGluR, Ionotropic, GluK1, 2728, Tocris Bioscience
Citations are publications that use Tocris products. Selected citations for ACET include:
Granger and Nicoll (2014) LTD expression is independent of glutamate receptor subtype. J Virol 6 15 PMID: 25071549
Kiyama et al (2019) Essential Roles of Tbr1 in the Formation and Maintenance of the Orientation-Selective J-RGCs and a Group of OFF-Sustained RGCs in Mouse. Cell Rep 27 900 PMID: 30995485
Do you know of a great paper that uses ACET from Tocris? Please let us know.
There are currently no reviews for this product. Be the first to review ACET and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.